Mymetics Corp (MYMX)

[bow-tie]

MERCK 2020 Q4 REPORT

Our Response to Covid-19*
Page 20
In addition, we are tapping into our existing collaborations to support projects that target Covid-19 vaccine and
therapy development. As part of our collaborations with Oxford University in the United Kingdom and Baylor
College of Medicine in Houston, Texas, USA, we supported the process development, manufacturing, and scale
up of their respective Covid-19 vaccines candidates.

Page 60
We also announced an extension of our ongoing collaboration with Baylor College of Medicine in Houston,
Texas, USA, which previously focused on vaccine development for tropical disease outbreaks, to now advance a
vaccine manufacturing platform for Covid-19. Our joint work supports the accelerated transition to Phase I
clinical trials, optimizing the production process to advance two Covid-19 vaccine candidates, including the CoV
RBD219-N1 vaccine candidate originally developed to target SARS.


https://www.emdgroup.com/investors/reports-and-financials/earnings-materials/2020-q4/us/2020-Q4-Report-NA.pdf